Common gastrointestinal effects (Phase 2 NEJM) Retatrutide GI side effects at 12 mg in the Phase 2 NEJM trial Effect Nausea Rate at 12 mg Up to 25% Effect Diarrhea Rate at 12 mg Up to 23% Effect Vomiting Rate at 12 mg Up to 26% Effect Constipation Rate at 12 mg Up to 16% GI symptoms were most common during dose escalation and were usually mild to moderate
Additionally, be sure you are not taking too much glutathione, as it can lead to an upset stomach or diarrhea
Our experts help you develop a balanced eating plan with vegetables, fruits, lean proteins, whole grains, and healthy fats
Conclusions and Future Perspectives Overall, GLP-1RAs are considered novel blood glucose lowering drugs used in the treatment of T2MD (229), owing to their advantages of lowering blood pressure, lowering the levels of fasting blood glucose, lowering HbA1c, inducing weight loss, and being associated with a low incidence of hypoglycemia